Carregant...
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma (HCC), has opened a window of hope after searching for effective agents to combat HCC for decades. However, the overall outcomes are far from satisfactory. One of the explanations is the genetic heterogeneity of...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Co., Limited
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3724962/ https://ncbi.nlm.nih.gov/pubmed/23898367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v5.i7.345 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|